

# **Shim-pack Arata LC Columns**

Unprecedented Resolution and Peak Shape of Basic Compounds

Even for LC columns that claim to be designed for basic compounds, adequate resolution often can not be obtained due to problems such as leading of highly polar basic compounds, peak shape deterioration of acidic compounds, or long equilibration time required for low ionic strength acidic mobile phase.

All of these issues have been solved with Shim-pack Arata that was specifically designed to give unmatched peak shape for basic compounds.

#### Unmatched Peak Shape Elegantly Designed for A Wide Range of Compounds

Unmatched peak shape of basic compounds could be achieved while maintaining good peak shape for acidic compounds with Shim-pack Arata LC columns. Even with low ionic strength acidic mobile phase, such as 0.1% formic acid containing mobile phase, excellent peak shape of both amitriptyline (a basic compound) and benzoic acid (an acidic compound) could be achieved.



Analysis of Amitriptyline and Benzoic Acid with The Mobile Phase with 0.1% Formic Acid

 Analytical Conditions

 Column
 : Shim-pack Arata C18

 Mobile Phase
 : 0.1% HCOOH in H<sub>2</sub>O / CH<sub>3</sub>CN = 70 / 30

 Flow Rate
 : 0.4 mL/min

 Detection
 : 254 nm

 Column Temp.
 : 40 °C

 Inj. Volume
 : 2 μL

Shim-pack / #

\*Gel Lot QC test analytical condition

### Excellent Separation Performance for Peptides Even with Weak Ion Paring Acids

In order to obtain good peak shape of peptides under reversed phase chromatography, TFA containing mobile phases are frequently used which the ion pairing effect is relatively strong. However, TFA could cause ion suppression in LC/MS (/MS) analysis. Excellent peak shape and separation performance for peptides could be achieved on the Shim-pack Arata LC column even with 0.1 % formic acid (weak ion paring acid) containing mobile phase.



| Analytical Conditions |                                      |              |  |  |  |  |  |
|-----------------------|--------------------------------------|--------------|--|--|--|--|--|
| Mobile Phase          | : A: 0.1% HCOOH in H <sub>2</sub> O  |              |  |  |  |  |  |
|                       | : B: 0.1% HCOOH in CH <sub>3</sub> C |              |  |  |  |  |  |
| Flow Rate             | : 0.4 mL/n                           | : 0.4 mL/min |  |  |  |  |  |
| Detection             | : 214 nm                             |              |  |  |  |  |  |
| Column Temp. : 40 °C  |                                      |              |  |  |  |  |  |
| Inj. Volume           | :1μL                                 |              |  |  |  |  |  |
| Sample                | : Angiote                            | nsin I       |  |  |  |  |  |
| Vial                  | : TORAST-H <sup>™</sup> Bio Vial     |              |  |  |  |  |  |
|                       |                                      |              |  |  |  |  |  |
| Colun                 | nn                                   | Asymmetry    |  |  |  |  |  |
| China maale A         | wate C10                             | 1.20         |  |  |  |  |  |

| Column              | Asymmetry |
|---------------------|-----------|
| Shim-pack Arata C18 | 1.26      |
| Typical ODS column  | 6.94      |
|                     |           |

\*Peptide is usually analyzed using gradient condition. Isocratic condition was used for this application in order to show the difference of LC columns more clearly. Result using gradient condition on Shim-pack Arata C18 was also evaluated and it was confirmed that angiotensin was fully eluted from the column with isocratic condition.

\*\*Acetonitrile concentration was adjusted in order that the retention time of peptide on each column become similar.

# Rapid Equilibration Even with Low Ionic Strength Acidic Mobile Phases

When analyzing basic compounds on a typical ODS column with low ionic strength acidic mobile phase, peak shape and long equilibration times are common problems. Shim-pack Arata LC columns can be rapidly equilibrated in low ionic strength acidic mobile phases yielding excellent peak shape and stable retention times.

| 1600                               | 160000  |  |   |      |      |         |         |        |      |      |      |
|------------------------------------|---|--|---|------|------|---------|---------|--------|------|------|------|
| 1500                               | 1   | Shim-pack Arata C18                        |   |      |      |         |         |        |      |      |      |
| 1200<br>1200<br>1100<br>900<br>800 | 00<br>00<br>00<br>00  | 2 Excellent peak sha<br>Rapid equilibratio | 2 Excellent peak shape &<br>Rapid equilibration |      |      |         |         |        |      |      |      |
| 700                                | 00  |  |   |      |      |         |         | 30 min |      |      |      |
| 50000                              |   |  |   |      |      |         | 60 min  |        |      |      |      |
| 40000 180 min                      |   |  |   |      |      |         |         |        |      |      |      |
| 20000                              |   |  |   |      |      | 360 min |         |        |      |      |      |
|                                    |   |  |   |      |      |         | 720 min |        |      |      |      |
|                                    | 0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00 4.25 4.50 4.75 min |  |   |      |      |         |         |        |      |      |      |
|                                    | Compounds   | Equilibration Time (min)                   | 10  | 30   | 60   | 120     | 180     | 240    | 360  | 480  | 600  |
| 1                                  | Doxtromothorphan  | Retention Time (min)                       | 0.8   | 0.8  | 0.8  | 0.8     | 0.8     | 0.8    | 0.8  | 0.8  | 0.8  |
|                                    | Dextromethorphan  | Symmetry Factor                            | 1.20  | 1.19 | 1.19 | 1.18    | 1.18    | 1.18   | 1.18 | 1.18 | 1.18 |
| 2                                  | Amitrintulino   | Retention Time (min)                       | 1.4   | 1.4  | 1.4  | 1.4     | 1.4     | 1.4    | 1.4  | 1.4  | 1.4  |

| 550<br>500  | Typical ODS column  |                  |   |      |        |      |      |      |   |      |      |      |      |       |
|---|---|------------------|---|------|--------|------|------|------|---|------|------|------|------|-------|
| 45000<br>40000<br>35000<br>25000<br>15000<br>15000<br>0 |   |                  | 2 Poor peak shape &<br>Long time required for equilibration |      |        |      |      |      | 30 min<br>60 min<br>180 min<br>360 min<br>720 min |      |      |      |      |       |
| _   | 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 n |                  |   |      | 9.5 mi | n    |      |      |   |      |      |      |      |       |
|   |   | Compounds        | Equilibration Time (min)                                    | 10   | 30     | 60   | 120  | 180  | 240   | 360  | 480  | 600  | 720  | CV(%) |
| 1   | ١.  | Doxtromothorphan | Retention Time (min)  | 1.9  | 1.8    | 1.7  | 1.6  | 1.5  | 1.5   | 1.5  | 1.4  | 1.4  | 1.4  | 10.4  |
|   |   | Symmetry Factor  |   | 3.28 | 3.14   | 3.01 | 2.70 | 2.63 | 2.56  | 2.51 | 2.49 | 2.56 | 2.49 | 10.2  |
| 2   | 2 Amitriptyline Retention Time (mir<br>Symmetry Factor                            |                  | Retention Time (min)  | 5.3  | 4.7    | 4.3  | 4.0  | 3.9  | 3.8   | 3.7  | 3.6  | 3.5  | 3.6  | 13.5  |
| 2   |   |                  | Symmetry Factor   | 4.23 | 4.23   | 4.35 | 4.22 | 4.13 | 4.17  | 4.09 | 4.02 | 3.99 | 3.90 | 3.1   |



1. Dextromethorphan

720 CV(%)

0.8 02

1.18 0.6

1.4 0.3

1.06 0.3



Analytical Conditions Instruments : NexeraX2MP\_M30A (STD Cell) Column : Shim-pack Arata C18 (3.0 × 75 mm, 2.2 μm) Typical ODS column (3.0 × 75 mm, sub 2 µm), Mobile Phase : 0.1% HCOOH in H<sub>2</sub>O / CH<sub>3</sub>CN = 70 / 30 Flow Rate : 0.4 mL/min Detection : 280 nm Column Temp. : 40 °C : 2 µL Inj. Volume : Amitriptyline, Sample Dextromethorphan

\*Both were new columns (shipping solvent : acetonitrile) and equilibrated with mobile phase without any conditioning. Basic drugs were analyzed after a certain period of time of equilibration and RT and symmetry factor of the drugs were compared.

Comparison of Column Equilibration in The Mobile Phase with 0.1% Formic Acid (Shim-pack Arata C18 vs. Typical ODS Column)

# **Ordering Information**

Symmetry Factor

#### Shim-pack Arata C18 2.2 µm

Amitriptyline

2

uν

| Length (mm) ID (mm) | 2.0          | 3.0          |
|---------------------|--------------|--------------|
| 50                  | 227-32801-01 | 227-32802-01 |
| 75                  | 227-32801-02 | 227-32802-02 |
| 100                 | 227-32801-03 | 227-32802-03 |
| 150                 | 227-32801-04 | 227-32802-04 |

#### Shim-pack Arata C18 5 um (Coming Soon)

|   | p p          |              |              |  |  |  |  |  |  |
|---|--------------|--------------|--------------|--|--|--|--|--|--|
|   | 2.0 × 50 mm  | 4.6 × 50 mm  |              |  |  |  |  |  |  |
|   | 2.0 × 75 mm  | 4.6 × 75 mm  |              |  |  |  |  |  |  |
|   | 2.0 × 100 mm | 3.0 × 100 mm | 4.6 × 100 mm |  |  |  |  |  |  |
|   | 2.0 × 150 mm | 3.0 × 150 mm | 4.6 × 150 mm |  |  |  |  |  |  |
| 1 |              | 4.6 × 250 mm |              |  |  |  |  |  |  |



## Shimadzu Corporation www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures. This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®". Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The contents of this publication are provided to you "as is" without warranty of any kind, and are subject to change without notice. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication.